Abstract: Perivascular epithelioid cell neoplasms (PEComa) are a family of rare mesenchymal tumors with hybrid myo-melanocytic differentiation. Although most PEComas harbor loss-offunction TSC1/TSC2 mutations, a small subset were reported to carry TFE3 gene rearrangements. As no comprehensive genomic study has addressed the molecular classification of PEComa, we sought to investigate by multiple methodologies the incidence and spectrum of genetic abnormalities and their potential genotype-phenotype correlations in a large group of 38 PEComas. The tumors were located in soft tissue (11 cases) and visceral sites (27) including uterus, kidney, liver, lung, and urinary bladder. Combined RNA sequencing and fluorescence in situ hybridization analysis identified 9 (23%) TFE3 gene-rearranged tumors, with 3 cases showing an SFPQ/PSF-TFE3 fusion and 1 case showing a novel DVL2-TFE3 gene fusion. The TFE3-positive lesions showed a distinctive nested/alveolar morphology and were equally distributed between soft tissue and visceral sites. In addition, novel RAD51B gene rearrangements were identified in 3 (8%) uterine PEComas, which showed a complex fusion pattern and were fused to RRAGB/OPHN1 genes in 2 cases. Other nonrecurrent gene fusions, HTR4-ST3GAL1 and RASSF1-PDZRN3, were identified in 2 cases. Targeted exome sequencing using the IMPACT assay was used to address whether the presence of gene fusions is mutually exclusive from TSC gene abnormalities. TSC2 mutations were identified in 80% of the TFE3 fusion-negative cases tested. Coexistent TP53 mutations were identified in 63% of the TSC2-mutated PEComas. Our results showed that TFE3-rearranged PEComas lacked coexisting TSC2 mutations, indicating alternative pathways of tumorigenesis. In summary, this comprehensive genetic analysis significantly expands our understanding of molecular alterations in PEComas and brings forth the genetic heterogeneity of these tumors.
P erivascular epithelioid cell neoplasms (PEComa) are rare mesenchymal tumors composed of epithelioid and pleomorphic cells with perivascular distribution, which usually express melanocytic and smooth muscle markers. Apart from tumors arising in soft tissue locations, the PEComa family includes renal angiomyolipoma, clear cell "sugar" tumor of the lung, and lymphangioleiomyomatosis, which are often characterized by a benign clinical course. 1 Although criteria for malignancy in PEComas have not been clearly established, clinically aggressive or malignant PEComas are typically large and usually show marked nuclear pleomorphism, increased mitoses, necrosis, and infiltrative margins. 2 Some members of the PEComa family (specifically angiomyolipoma and lymphangioleiomyomatosis) occur in the setting of tuberous sclerosis complex (TSC) syndrome. Furthermore, a high frequency of syndromic and sporadic PEComas have loss-of-function mutations in TSC1 or TSC2 genes, 3, 4 with subsequent activation of the mammalian target of rapamycin (mTOR) pathway, 5 which has been targeted therapeutically with mTOR inhibitors. 6, 7 TFE3 is a member of the MiT family of transcription factors, which also includes MiTF, TFEB, and TFEC. 8 TFE3 gene fusions have been demonstrated in several types of neoplasia, such as alveolar soft part sarcoma, resulting in an ASPL-TFE3 fusion, 9 and pediatric renal cell carcinomas (RCCs), with various TFE3 gene fusions. 10 Recently, a small subset of PEComas has been shown to harbor TFE3 gene fusions, [11] [12] [13] [14] [15] with a single-case report showing an SFPQ/PSF-TFE3 gene fusion. 16 In this study, we performed a comprehensive genomic characterization by transcriptome analysis of PEComas of various anatomic sites to establish the incidence and spectrum of gene fusions, as well as possible correlations between genetic signature and clinical presentation. In addition, we sought to investigate whether TFE3 rearrangements or other gene fusion abnormalities identified are mutually exclusive from the TSC1/TSC2 loss-of-function mutations, to support a dichotomy of genetic alterations in PEComas with obvious therapeutic implications.
MATERIALS AND METHODS
The Department of Pathology files at Memorial Sloan Kettering Cancer Center and the personal consultation files of the senior author (C.R.A.) were searched for cases of PEComa between 2000 and 2014. The criteria for the selection included a typical morphology and immunoprofile and available tissue for fluorescence in situ hybridization (FISH) and/or molecular studies. The study focused mainly on the PEComa group, and most other benign entities included in this family, such as triphasic angiomyolipomas and lymphangioleiomyomatosis, were excluded from the study. Hematoxylin and eosin and immunohistochemical staining analyses performed at the time of diagnosis were reviewed. The gross and microscopic findings, including tumor size, anatomic location, tumor morphology, mitoses (per 10 high-power fields [HPF] ), and presence of necrosis were recorded. Clinical and follow-up data were obtained from the clinical database. The study was approved by the Institutional Review Board (IRB# 02-060/WA0079-14 MSKCC).
RNA Sequencing
Eleven cases were analyzed by RNA sequencing. Total RNA was prepared for RNA sequencing in accordance with the standard Illumina mRNA sample preparation protocol (Illumina). Briefly, mRNA was isolated with oligo(dT) magnetic beads from total RNA (10 mg) extracted from each case. The mRNA was fragmented by incubation at 941C for 2.5 minutes in fragmentation buffer (Illumina). To reduce the inclusion of artifactual chimeric transcripts due to random priming of transcript fragments into the sequencing library because of inefficient A-tailing reactions that lead to self ligation of blunt-ended template molecules, 17 an additional gel size-selection step was introduced before the adapter ligation step. The adaptor-ligated library was then enriched by polymerase chain reaction (PCR) for 15 cycles and purified. The library was sized and quantified using the DNA1000 kit (Agilent) on an Agilent 2100 Bioanalyzer according to the manufacturer's instructions. Paired-end RNA sequencing at read lengths of 50 or 51 bp was performed with the HiSeq 2000 (Illumina). Across the samples, an average of 47.5M pair-end reads were generated per sample corresponding to 4.75B bases per sample.
Analysis of RNA Sequencing Results With FusionSeq
All reads were independently aligned with the CA-SAVA 1.8 software provided by Illumina against the human genome sequence (hg19) and a splice junction library, simultaneously. The splice junction library was generated by considering all possible junctions between exons of each transcript. We considered the University of California, Santa Cruz (UCSC) Known Genes annotation set 18 to generate this library using RSEQtools, a computational method for processing RNA-seq data. 19 The mapped reads were converted into Mapped Read Format 15 and analyzed with FusionSeq 20 to identify potential fusion transcripts. FusionSeq is a computational method successfully applied to paired-end RNA-seq experiments for the identification of chimeric transcripts. [21] [22] [23] Briefly, paired-end reads mapped to different genes are first used to identify potential chimeric candidates. A cascade of filters, each taking into account different sources of noise in RNA sequencing experiments, was then applied to remove spurious fusion transcript candidates. Once a confident list of fusion candidates was generated, they were ranked with several statistics to prioritize the experimental validation. In these cases, we used the DASPER score (Difference between the observed and Analytically calculated expected SPER); a higher DASPER score indicated a greater likelihood that the fusion candidate was authentic and did not occur randomly. See Sboner et al 20 for further details about FusionSeq.
In addition, RNA-seq data were analyzed for gene mutation calls. Samtools mpileup (http://samtools.sourceforge.net/mpileup.shtml) was used to generate a BCF file from the aligned BAM file, and only potential variants were reported. Downstream Variant Filter from Samtools was applied, and variants were excluded if the quality score was <40 or RNA-seq read coverage was <20. The Variant Effect Predictor tool provided by Ensembl (http://useast. ensembl.org/info/docs/tools/vep/index.html) was used to detect variants with missense mutations in the 340 genes from the IMPACT panel. Potential missense locations were compared with NCBI dbSNP (http://www.ncbi.nlm.nih.gov/ snp/). Sanger PCR validation was performed for novel mutations or those occurring with a frequency <1%. 
Reverse Transcription PCR

DNA PCR
Genomic DNA was isolated either from fresh-frozen or archival paraffin tissue, as described previously. 24 Targeted PCR for mutation validation and long range PCR for gene fusion was performed for 30 25 The genomic location of each BAC set was verified by hybridizing them to normal metaphase chromosomes. Two hundred successive nuclei were examined using a Zeiss fluorescence microscope (Zeiss Axioplan, Oberkochen, Germany), controlled by Isis 5 software (Metasystems, Newton, MA). A positive score was interpreted when at least 20% of the nuclei showed a breakapart signal. Nuclei with an incomplete set of signals were omitted from the score.
Targeted Exome Sequencing
We profiled 11 PEComas for genomic alterations in 340 key cancer-associated genes using our IMPACT assay (Integrated Mutation Profiling of Actionable Cancer Targets). This assay utilizes solution phase hybridization-based exon capture and deep-coverage massively parallel DNA sequencing. 26 Custom oligonucleotides were designed to capture all protein-coding exons and select introns of commonly implicated oncogenes, tumor-suppressor genes, and members of pathways deemed actionable by targeted therapies. Tumors and patient-matched normal tissues were run in parallel for every case. Barcoded sequence libraries were prepared according to manufacturers' protocols (New England Biolabs, Ipswich, MA; Kapa Biosystems, Wilmington, MA) using 36 to 250 ng of genomic DNA as input. Libraries were pooled and input to a single exon capture reaction as previously described. 27 To prevent off-target hybridization, a pool of blocker oligonucleotides complementary to the full sequences of all barcoded adaptors was spiked in to a final total concentration of 10 mM. DNA was subsequently sequenced on an Illumina HiSeq 2500 to generate paired-end 100 bp reads. Sequence data were demultiplexed using CASAVA, and reads were aligned to the reference human genome (hg19) using the Burrows-Wheeler Alignment tool. 28 Local realignment and quality score recalibration were performed using the Genome Analysis Toolkit (GATK) according to GATK best practices. 29 We achieved a mean unique sequence coverage of 792Â per tumor. Sequence data were analyzed to identify 3 classes of somatic alterations: single-nucleotide variants, small insertions/deletions (indels), and copy number alterations. Single-nucleotide variants and indels were called using muTect and SomaticIndelDetector, respectively. 29, 30 The mean sequence coverage was calculated using the DepthOfCoverage tool in GATK and was used to compute copy number as described previously. 22 Increases and decreases in the coverage ratios (tumor:normal) were used to infer amplifications and deletions, respectively.
RESULTS
Pathologic Features and Ancillary Findings
Thirty-eight PEComa cases were selected for the study (Table 1 ). There were 23 female and 15 male patients, with ages ranging from 24 to 79 years (median age 56). Eleven tumors were located in the soft tissue, including thigh, calf, pelvis, buttock, retroperitoneum, intra-abdominal, back, mediastinum, paraspinal, and perirectal. Other visceral sites included uterus, 11 cases (4 primary and 7 recurrences); gastrointestinal (GI)/liver and pancreas, 7; kidney, 6; and 1 each in urinary bladder, lung, and brain.
Transcriptome Analysis Identifies Novel Gene Fusions
RNA Sequencing and FusionSeq analysis was performed on 11 cases. Gene fusion candidates were identified in 5 cases. Two of the cases showed a TFE3-associated gene fusion with 1 showing an SFPQ/PSF-TFE3 gene fusion (previously reported by Tanaka and colleagues) and the other showing a novel DVL2-TFE3 gene fusion. Three novel non-TFE3 gene fusions were identified including RAD51B-RRAGB/OPHN1, HTR4-ST3GAL1, and RASSF1-PDZRN3. Six of the cases showed no evidence of gene fusions. These gene fusions were validated by the FISH technique and RT-PCR in all of 5 cases. FISH was also used to screen all of the remaining study cases for possible recurrent gene fusions.
TFE3 Gene Rearrangements Are Seen in a Subset of PEComa With Distinct Nested Morphology
FISH analysis for TFE3 was performed on all study cases and identified TFE3 gene rearrangements in 9 (23%) PEComa cases. There were 7 female and 2 male patients, ranging in age from 33 to 69 years (median 56). This group spanned broad anatomic sites, including 5 soft tissue, 1 uterine, 2 GI, and 1 lung. Tumor size, available in 4 cases, ranged from 1 to 8 cm. All except 1 case showed a strikingly similar epithelioid morphology with abundant clear to granular cytoplasm, arranged in a nested to alveolar pattern (Fig. 1, Supplementary Table 3 , Supplemental Digital Content 1, http://links.lww.com/ PAS/A255). One case (case 8) showed spindle to ovoid cells in sheet-like arrangement with scattered pleomorphic cells (Fig. 1I) . Mitotic activity was low in all cases, with most cases showing 0 to 1 mitosis/10 HPF. Immunohistochemically, 6 of the 9 cases showed positivity for HMB45 (Fig. 1) , and all 5 cases tested showed strong and diffuse TFE3 positivity (including the 3 cases that were negative Novel DVL2-TFE3 Gene Fusion Identified in Soft Tissue PEComa DVL2-TFE3 fusion was identified in 1 case (case 4) by the RNA-seq method (Fig. 2) . DVL2 (disheveled segment polarity protein 2) is located on chromosome 17 (17p13.1). Experimental validation by RT-PCR confirmed a transcript composed of DVL2 exon 4 fused to TFE3 exon 7. FISH break-apart assay for TFE3 and DVL2 confirmed rearrangements in both genes. DNA PCR further confirmed the intronic break showing DVL2 exon 5 fused to TFE3 intron 6, with an intercalated small fragment of antiparallel sequence of TFE3 exon 6 and TFE3 intron 5 (Fig. 2) .
None of the other TFE3-rearranged PEComas, analyzed by FISH, showed DVL2 gene rearrangement.
Five of the TFE3-rearranged PEComas lacking a fusion partner were also analyzed by FISH for PRCC gene abnormalities, one of the known TFE3 gene partners in RCCs. 31 However, no PRCC gene rearrangements were identified. Novel Recurrent RAD51B Gene-associated Fusions Identified in Uterine PEComa RNA sequencing and FusionSeq analysis in 1 uterine case (case 10) identified 2 fusion transcript candidates, both involving RAD51B gene on the 14q23-24.2 locus (Fig. 3) . One of the fusion partners was RRAGB on the Xp11.21 locus, whereas the other was the OPHN1 gene on the Xq12 locus. Both RAD51B-RRAGB and RAD51B-OPHN1 fusions were confirmed and validated by FISH, RT-PCR, and DNA PCR methodologies. For the RAD51B-RRAGB fusion, RT-PCR showed fusion of the RAD51B exon 8 to RRAGB exon 2 with an intervening 120 bp intronic sequence of Xp11.21. FISH break-apart assays confirmed rearrangements in both RAD51B and RRAGB genes. For the RAD51B-OPHN1 fusion, RT-PCR confirmed the fusion transcript between RAD51B exon 3 with OPHN1 exon 17 (Fig. 3) . FISH fusion assay showed the fused signal of RAD51B and OPHN1 genes (Fig. 3) . Long-range DNA PCR confirmed the intronic break with intron 3 of RAD51B fused to intron 16 of OPHN1.
FISH for RAD51B abnormalities was performed on 25 additional TFE3-negative PEComas and identified 2 additional positive cases, both originating from the uterus. One of the RAD51B-positive PEComas (case 11) was similarly associated with rearrangements in both RRAGB and OPHN1 genes by FISH. In the remaining RAD51B-rearranged PEComa (case 12), no gene partner was identified.
Morphologically, these 3 cases showed varied morphology. Case 10 showed a cellular epithelioid neoplasm, displaying a solid and sheet-like arrangement, with minimal cytoplasm and nuclei with prominent nucleoli, somewhat reminiscent of a small blue round cell tumor (Fig. 4A) . Case 11 showed epithelioid cells arranged in small nests with focal areas of sclerosis (Fig. 4B) . Case 12 showed spindle cells with scattered pleomorphism in a partially sclerotic background with focal areas showing a hemangiopericytoma-like vascular pattern (Fig. 4C) . Strikingly, all 3 cases showed increased mitotic activity of >10 mitoses/10 HPF. Necrosis was identified in 1 case. Furthermore, a consistent pattern of smooth muscle immunoprofile was discerned in all 3 cases, with reactivity for both SMA and desmin. In addition, all 3 cases were positive for HMB45, and 2 of the tested cases also showed MITF positivity.
Additional Nonrecurrent HTR4-ST3GAL1 and RASSF1-PDZRN3 Gene Fusions in PEComa RNA sequencing on 2 additional PEComa cases (cases 13 and 14) identified novel HTR4-ST3GAL1 and RASSF1-PDZRN3 gene fusions. Both of these gene fusions were validated by RT-PCR and FISH analysis. Case 13 was a pelvic PEComa composed morphologically of intersecting fascicles of spindle cells, more reminiscent of a smooth muscle neoplasm (Fig. 4D) . Immunohistochemically, the tumor expressed SMA, desmin, MITF, and HMB45 (focally). Case 14 occurred in the urinary bladder wall and displayed a mixed spindle and epithelioid morphology with cells arranged in fascicles and a partially nested pattern (Fig. 4E) . Lesional cells showed moderate clear cytoplasm and spindle to round nuclei with prominent nucleoli. Immunohistochemically, the tumor expressed SMA, MITF, and HMB45 and was negative for desmin.
FISH analysis on the remaining PEComa cases failed to identify additional cases with these gene fusions, indicating that these are most likely nonrecurrent genetic events.
PEComas With No Identifiable Gene Fusions
In a majority of PEComas (24 of 38, 63%), no gene fusions were identified. These tumors were located at various anatomic sites, including soft tissue and viscera (GI, gynecologic [GYN] , and renal). Tumor morphology (Figs. 4F-I ) was predominantly that of epithelioid cells with clear to granular cytoplasm arranged in nests and cords (17 of 24 cases). Some of the cases (3 of 24) showed a mixed spindle and epithelioid phenotype, and other cases (4 of 24) showed a purely spindled morphology, similar to a smooth muscle tumor. One case (case 27) showed a sclerosing pattern with spindle cells in a densely sclerotic background, so-called sclerosing PEComa (Fig. 4I) . Nuclear pleomorphism was noted in 11 of 24 cases.
Coexistent TSC2 and TP53 Mutations Identified in TFE3 Fusion-negative PEComas by Targeted Exome Sequencing
Targeted exome paired-end sequencing analysis using the IMPACT assay was performed on a group of 11 PEComa cases with matched normal tissue available. The 11 cases tested included 3 TFE3-rearranged PEComas, 1 PEComa with RAD51B-RRAGB/OPHN1 fusion, 1 PEComa with HTR4-ST3GAL1, and 6 PEComas with no known gene fusions. One fusion-negative PEComa (case 16) had the TSC2 gene sequenced as part of a prior study. 6 In 1 other fusion-negative PEComa (case 33), RNA-seq data were analyzed for possible mutations. Overall, 8 of 13 (62%) cases tested showed TSC2 gene mutations ( Table 1) . None of the 3 TFE3-rearranged PEComas tested showed TSC1/TSC2 or TP53 mutations. Upon excluding the TFE3 fusion-positive PEComas, the incidence of TSC2 gene abnormalities was higher with 8 of 10 (80%) cases showing mutations. Interestingly, 5 of the 8 (63%) cases with TSC2 mutations also showed coexistent TP53 mutations. The only case of RAD51B fusion-positive PEComa (case 10) tested showed both TSC2 and TP53 gene mutations. Mutations in 4 of the 8 positive cases were also validated using Sanger sequencing methodology (Table 1) .
Treatment
Treatment history was available on 29 cases of the study. Sixteen cases were treated by surgical resection only. One case (case 2) received postoperative radiation therapy after local recurrence. Twelve cases received systemic therapy with cytotoxic chemotherapy (including gemcitabine, docetaxel, doxorubicin, ifosfamide, cyclophosphamide, irinotecan, dacarbazine, paclitaxel), tyrosine kinase inhibitors (pazopanib, sunitinib, and sorafenib), and mTOR inhibitors (sirolimus and everolimus). In 1 case of PEComa of the liver in a 37-year-old woman (case 16), treatment with an mTOR inhibitor (everolimus) was given in the neoadjuvant setting with good clinical and pathologic response (previously reported in Dickson et al 6 ). In all other cases, systemic therapy was given for recurrent or relapsed disease. Of note, some patients in this series were treated in the era before the discovery of the activity of mTOR inhibitors in PEComa and thus were never treated with this class of drugs.
In the TSC2 mutation-positive group of 8 cases, mTOR inhibitors were used in 4 cases. One case (case 16) received the drug in a neoadjuvant setting, as described above, and showed a good clinical response. In another case (case 22), treatment showed initial response, followed by progression of disease. No significant response was seen in 2 other cases.
Clinical Follow-up
Follow-up information was available on 30 of the 38 study cases (Table 1 ) with duration ranging from 2 to 140 months. Ten patients developed local recurrence (LR), and 10 patients developed distant recurrence (DR), including 5 patients who developed both LR and DR. At the time of last follow-up, 20 patients had no evidence of disease (NED), 2 were alive with disease (AWD), 7 had died of disease (DOD), and 1 had died of other causes (DOO).
In the TFE3 fusion-positive group, follow-up information was available on 4 patients, ranging from 12 to 51 months, of which 2 developed LR. At last follow-up, 3 patients were NED, and 1 was AWD.
In the RAD51B fusion-positive group, follow-up information was available on all the 3 cases, ranging from 16 to 38 months. All 3 patients developed DR, of which 1 developed both LR and DR. At last follow-up, 2 patients had NED and 1 had DOD.
In PEComas with TSC2 gene mutations, follow-up information was available in all of the 8 cases, ranging from 7 to 140 months. Two patients developed LR, and 4 patients developed DR. At last follow-up, 4 patients DOD, 1 patient DOO, and 3 had NED. Looking exclusively at the subset of cases having both TSC2 and TP53 mutations, follow-up ranged from 7 to 94 months, with 1 patient developing LR, and 3 patients developing DR. At last follow-up, 3 patients DOD, 1 patient DOO, and 1 had NED.
DISCUSSION
TFE3 gene fusions were initially reported in PEComa by Tanaka et al, 16 who reported a GI PEComa with an SFPQ/PSF-TFE3 gene fusion. Subsequently, Argani et al 11 reported a series of 29 PEComas, of which 4 (13%) cases showed TFE3 gene rearrangements by FISH. Two of these 4 cases were tested for PSF-TFE3 fusion by RT-PCR but were negative. None of the other recent studies of PEComa 32, 33 has identified TFE3 gene fusions as recurrent events in 8 cases tested by FISH. The goal of our study was to provide a molecular characterization of PEComas of different clinical presentations by applying the latest transcriptome analysis, a highly sensitive method best suited for novel fusion gene discovery. The cases were first screened for the known TFE3 and SFPQ/PSF gene rearrangements by FISH, followed by RNA sequencing in the negative cases with available frozen tissue. Additional targeted sequencing for detection of somatic DNA mutations (ie, TSC1/TSC2 lossof-function mutations) was applied focusing mainly on the fusion-positive cohort, to test the hypothesis of mutually exclusive abnormalities from the TFE3-related fusions or alternative translocations. This comprehensive genomic analysis identified 9 (23%) cases of TFE3 gene fusion-positive PEComas, of which 3 showed an SFPQ/ PSF-TFE3 gene fusion. This gene fusion emerges as the most prevalent genetic event among TFE3-rearranged PEComas, interestingly all occurring in soft tissue PEComas. The SFPQ/PSF-TFE3 gene fusion results from a t(X;1) (p11.2;p34) translocation, which has been previously reported in a GI PEComa, 16 as well as in a small subset (1.2%) of TFE3 fusion-associated RCCs. 34 An additional novel DVL2-TFE3 fusion was identified by RNA sequencing in a soft tissue PEComa, resulting from a t(X;17)(p11.2;p13.1) translocation. As expected from most other TFE3-related fusions, which result in TFE3 oncogenic activation, DVL2-TFE3 fusion also demonstrated high levels of TFE3 mRNA by transcriptome analysis. DVL2 encodes a member of the dishevelled (dsh) protein family, which may play a role in the signal transduction pathway mediated by multiple Wnt proteins. 35 Similar to prior reports of TFE3-associated PEComa 11, 16 and other TFE3 fusion-positive neoplasms, such as alveolar soft part sarcoma and Xp11.2 RCC, the TFE3-rearranged PEComa in our study showed similar morphologic findings of a distinctively epithelioid nested neoplasm, with abundant clear to granular eosinophilic cytoplasm and relatively monotonous nuclei with low mitotic activity. Only 1 TFE3-positive tumor showed a more spindle cell to ovoid morphology with scattered pleomorphic cells. In contrast to Argani et al, 11 who reported a mean age of 23.6 years for TFE3 fusion-positive PEComas as opposed to 53 years for TFE3 fusion-negative PEComas, our study did not reveal such an age difference between these 2 genetically distinct PEComa subsets (50 vs. 57 mean age).
In addition to the TFE3-rearranged subgroup, our findings further point out to another genetic subset, characterized by recurrent RAD51B gene fusions seen only in uterine PEComas. Of the 3 positive cases identified, 2 showed complex RAD51B-RRAGB/OPHN1 gene fusions. No partner gene was identified in 1 remaining case. Interestingly, RAD51B-associated fusions, RAD51B-HMGIC, have been previously identified in a subset of uterine leiomyoma. 36, 37 The shared RAD51B gene abnormalities in uterine leiomyomas and uterine PEComas (expressing desmin) raise questions regarding a morphologic spectrum or possible common pathogenesis between these 2 neoplasms in the uterus. The distinction between uterine leiomyosarcomas and PEComas has been quite challenging. Not surprisingly, all 3 RAD51B-rearranged PEComas were initially interpreted as leiomyosarcomas. Only after the recurrent disease was examined or melanocytic markers tested, the lesions were recognized as uterine PEComas. To complicate issues further, studies have pointed out an immunoprofile overlap between leiomyosarcoma and PEComa of the GYN tract, showing HMB45 reactivity (ie, "leiomyosarcomas with HMB45 positivity"). 38, 39 In our study, 1 of the 3 tumors with RAD51B fusion also showed TSC2 and TP53 mutations, further supporting the classification of these tumors as PEComas. Further studies are needed to investigate whether these observations point to a common disease spectrum or merely overlapping immunophenotype of 2 genetically distinct pathologic entities. RAD51B-PLAG1 gene fusion has also been reported in a case of lipoblastoma. 40 The protein encoded by this gene is a member of the RAD51 protein family, with important function in the DNA repair by homologous recombination. This protein has been shown to form a stable heterodimer with the family member RAD51C, which further interacts with the other family members, such as RAD51, XRCC2, and XRCC3. RAD51B overexpression was found to cause cell cycle G1 delay and cell apoptosis, suggesting a role of this protein in sensing DNA damage. 41 The morphologies of the 3 RAD51B-positive PEComas were relatively different from each other and from the TFE3-rearranged group, with only 1 of the 3 cases showing a nested morphology.
Our study included a broad spectrum of clinical presentations in an attempt to identify potential correlations between the genetic signatures and anatomic locations in PEComas. The largest subset was originating from the GYN tract (11 cases), which showed a wide variability in morphologic features, including tumors composed of nests of epithelioid cells with clear cytoplasm, whereas others displayed a mixed spindle and epithelioid phenotype, with rare cases showing a pure spindle cell pattern reminiscent of smooth muscle tumors. This morphologic spectrum is in keeping with other studies that have focused on PEComa from the GYN tract 2, 33 or from other visceral sites, such as the GI tract. 42 Similar to PEComas from other sites, only a subset of uterine PEComas show TFE3-associated gene fusions. In the report by Argani et al, 11 only 1 of the 4 TFE3 fusion-positive cases was from the uterus, this being the only reported case so far. Schoolmeester et al 33 tested 3 uterine PEComas for TFE3 gene rearrangements by FISH, but none was found to be positive. In our study, 1 of the 9 (11%) TFE3 fusion-positive PEComas was from the uterus. In addition, the novel RAD51B gene fusion identified in our study was seen exclusively in uterine PEComa. Our study findings indicate that PEComas of the uterus/GYN tract, similar to the soft tissue and other visceral PEComas, show phenotypic and genotypic heterogeneity.
Pan et al, 43 using comparative genomic hybridization, identified losses of chromosome 16p involving the region of TSC2 gene in PEComa. Apart from the 16p deletions, they also identified losses in chromosome 17p involving the TP53 gene. This study showed similar alterations in both renal and extrarenal PEComas. Subsequently, the same group, 3 using loss of heterozygosity analysis, identified loss of heterozygosity of the TSC2 locus and mTOR activation in PEComa. Qin et al, 4 studying a group of renal angiomyolipomas, identified TSC2 mutations in 7 of 8 cases tested, with most of the mutations representing deletions. No mutations were identified in the TSC1 gene. Malinowska et al 44 compared 4 cases each of TFE3 fusion-positive and TFE3-negative PEComas, and reported that TSC2 alterations were exclusively identified in PEComas lacking TFE3 gene fusions and postulated that TFE3-rearranged PEComas have a different pathogenetic mechanism that does not involve the TSC2 gene through mutation or allelic loss. Our study, using next-generation targeted exome sequencing, identified TSC2 mutations in 8 of 11 (72%) PEComas lacking TFE3 rearrangements. A subset of 5 cases showed concurrent TP53 mutations. No TSC1 mutations were identified. Given that TSC2 deletions are also found in the benign triphasic angiomyolipomas, it appears that TSC2 loss is an early event in the PEComa family, and additional secondary genetic alterations determine the biology and behavior of the tumor.
In conclusion, this study significantly expands our understanding of molecular alterations (Fig. 5 ) in PEComas and brings forth the morphologic and genetic heterogeneity of these tumors. TFE3 rearrangements are seen in 23% of all PEComa cases studied and spanned a broad spectrum of locations. Among this group, the SFPQ/PSF-TFE3 emerges as the most prevalent fusion, accounting for about one third of cases, with rare tumors exhibiting an alternative DVL2-TFE3 fusion. The expected mechanism of tumorigenesis is through oncogenic activation of TFE3, likely by the acquisition of a strongly expressed promoter. Although our study was not designed for determining an accurate prevalence of TSC1/ TSC2 gene mutations in PEComa cohorts, we wanted to address the specific question of mutually exclusive abnormalities within the fusion-positive group. Thus, our targeted next generation sequencing corroborated with mutation calls from the RNA sequencing was able to exclude the presence of TSC1/TSC2 and p53 mutations in the TFE3-positive cohort. This finding not only adds to the speculation that TFE3-rearranged tumors have a different pathogenesis and most likely represent a distinct subgroup of PEComas, but also points to the potential differences in therapeutic targeting. On the basis of prior case reports, 6, 7, 45 the current reflex treatment for most PEComas consists of mTOR inhibitors, which may not be as effective in this genetic subgroup. However, this hypothesis would have to be tested in a larger patient cohort, as the response of TFE3-rearranged tumors to mTOR inhibitors is largely unknown. Alternative drugs, such as crizotinib and tivantinib (MET inhibitors) are being explored in other TFE3-overexpressed sarcomas (ie, alveolar soft part sarcomas). 46 In contrast, TSC2 mutations and coexisting TP53 mutations were identified in a subset of tumors sharing a spindle/pleomorphic morphology spanning soft tissue and visceral anatomic sites, with possibly more aggressive behavior. Given that TSC2-mutated, TFE3 fusion-negative PEComas from both soft tissue and visceral locations show similar morphology and genetic alterations, it is probably more appropriate to regard these tumors as a single group rather than as site-specific entities.
